Hosted on MSN10d
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
STAT10d
Eli Lilly hits rare stumble, as sales and earnings disappoint
Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...
The Associated Press - Business News on MSN10d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
NBC Washington10d
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Demand for weight loss and diabetes injections has outpaced ... from production to delivery. Ricks said Eli Lilly had yet to begin what the company calls "demand-stimulating activities," or ...
ABC News11d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Sales of Lilly's diabetes treatment Mounjaro ... wind up being more than twice what the company registered for 2023. Shares of Indianapolis-based Eli Lilly and Co. were down 6%, or $57.02, to ...